EAM Investors’s LENZ Therapeutics LENZ Stock Holding History

EAM Investors’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-80,187	Closed	-$3.68M	–	366
2025 Q3	$3.68M	Buy	+80,187	New	+$2.95M	0.42%	118

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

EAM Investors's LENZ Position: Q4 2025 in Review

EAM Investors sold out of LENZ Therapeutics (LENZ) in Q4 2025, closing a stake of 80,187 shares — an estimated $3.68M sold.

EAM Investors first reported a position in LENZ in Q3 2025 and held it in 1 quarter. The position peaked at $3.68M in Q3 2025. 160 funds tracked by Wall St. Rank hold LENZ as of Q4 2025.

EAM Investors reported no remaining LENZ Therapeutics position as of Q4 2025 after selling out during the quarter.
EAM Investors sold 80,187 LENZ Therapeutics shares in Q4 2025, an estimated $3.68M.
EAM Investors first reported a position in LENZ Therapeutics in Q3 2025 and held it in 1 quarter.
EAM Investors's LENZ Therapeutics position peaked at $3.68M in Q3 2025.
160 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2025.

Based on EAM Investors's 13F filing for Q4 2025, filed 12 Feb 2026.